Last $11.04 USD
Change Today -0.22 / -1.95%
Volume 1.1M
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

affymetrix inc (AFFX) Snapshot

Open
$11.19
Previous Close
$11.26
Day High
$11.25
Day Low
$10.95
52 Week High
01/20/15 - $11.89
52 Week Low
04/11/14 - $6.25
Market Cap
812.4M
Average Volume 10 Days
1.7M
EPS TTM
$-0.04
Shares Outstanding
73.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AFFYMETRIX INC (AFFX)

affymetrix inc (AFFX) Related Businessweek News

No Related Businessweek News Found

affymetrix inc (AFFX) Details

Affymetrix, Inc. provides life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, Latin America, and Asia. The company operates in two segments, Affymetrix Core and eBioscience. The Affymetrix Core segment is engaged in the development, manufacture, and commercialization of systems for genetic analysis in the life sciences and diagnostic industry. This segment develops and markets GeneChip gene expression products and services; genotyping product line, such as the Axiom product line; arrays and assays with clinical research applications, such as the CytoScan and OncoScan products; QuantiGene line of singleplex and multiplex assays to serve customers in the research and translational medicine markets; and GeneTitan family of products consisting of the GeneTitan instrument system that runs genotyping and gene expression array plates. It also offers life science reagents, such as ExoSAP-IT for a reagent for the clean-up of polymerase chain reaction, and HotStart-IT reagents to inhibit primer dimer formation; enzymes; purification kits; and biochemicals for life science researchers. The eBioscience segment is involved in the development, manufacturing, marketing, and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging, and other protein-based analyses. This segment offers a portfolio of antibodies and reagents, as well as a range of the QuantiGene and Procarta assay portfolio. The company sells its products directly and through third party distributors to genomic research centers, academic institutions, government, and private laboratories, as well as pharmaceutical, diagnostic, and biotechnology companies. Affymetrix, Inc. was founded in 1991 and is headquartered in Santa Clara, California.

1,100 Employees
Last Reported Date: 03/3/14
Founded in 1991

affymetrix inc (AFFX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $498.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $281.8K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $376.5K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $331.3K
Compensation as of Fiscal Year 2013.

affymetrix inc (AFFX) Key Developments

Affymetrix Inc. Announces Board Changes

Affymetrix Inc. announced that Founder and Chairman, Stephen Fodor, Ph.D., will retire from the company's Board of Directors effective January 30, 2015. He has served on the Board since the Company's inception, and has been Chairman since 1999. The Board of Directors elected Jami Nachtsheim as Chairwoman of the Company's Board of Directors, succeeding Dr. Fodor. Ms. Nachtsheim has served as a director of the Company since 2010 and the Company's lead independent director since 2013. Dr. Fodor founded the company in 1992, initially serving as its Scientific Director. He was named the company's President in 1993 and CEO from 1997 to 2008. Since 2011, Frank Witney, Ph.D., has served as the company's President and CEO and an Affymetrix Board Director.

Affymetrix, Inc. Appoints Merilee Raines as Member of the Board of Directors and Audit Committee

Affymetrix, Inc. has appointed Merilee Raines as a new member of the board of directors. Ms. Raines will serve as a member of the Audit Committee. Ms. Raines served as CFO of IDEXX Laboratories (IDXX), Inc. from 2003 until her retirement in 2013. Prior to becoming CFO, she held management positions with IDEXX Laboratories, including vice president of Finance, Treasurer, Director of Finance, and Controller. Ms. Raines is also a member of the Board of Directors of Watts Water Technologies (WTS) and Aratana Therapeutics (PETX).

Affymetrix Announces Preliminary Unaudited Sales Results for the Fourth Quarter of 2014; Appoints Merilee Raines to board's audit committee

Affymetrix announced preliminary unaudited sales results for the fourth quarter of 2014. For the quarter, the company reported revenues of $93 million, up 2.2% year on year. The company also announced that Merilee Raines has been appointed the board's audit committee effective January 12, 2015. Raines served as CFO of IDEXX Laboratories (IDXX) from 2003 until her retirement in 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AFFX:US $11.04 USD -0.22

AFFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $38.53 USD -1.25
Luminex Corp $17.65 USD -0.25
Pacific Biosciences of California Inc $8.04 USD -0.13
Sequenom Inc $3.68 USD 0.00
Takara Bio Inc ¥1,352 JPY -3.00
View Industry Companies
 

Industry Analysis

AFFX

Industry Average

Valuation AFFX Industry Range
Price/Earnings 100.0x
Price/Sales 2.4x
Price/Book 3.1x
Price/Cash Flow 2,227.3x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AFFYMETRIX INC, please visit www.affymetrix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.